Please login to the form below
Yescarta
This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.
Kite’s CAR-T therapy Yescarta granted EC approval in second-line lymphoma
Additionally, Yescarta demonstrated a 2.5 fold increase in patients who were alive at two years without disease progression or need for additional cancer treatment versus SOC. ... Moreover, improvements in EFS with Yescarta were consistent across key
Latest news
-
Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury
Yescarta (axicabtagene ciloleucel) reached $175m in relapsed/refractory large B-cell lymphoma and relapsed/refractory indolent follicular lymphoma in both the US and Europe.
-
BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
Kite has already seen success with its own CAR T treatments, which includes Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel). ... Meanwhile, Yescarta is used to treat follicular lymphoma and is also approved in the US for the
-
Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study
After a median follow-up of two years, Yescarta showed a 60.2% improvement in event-free survival (EFS) compared to SOC. ... Yescarta has been instrumental in transforming outcomes for patients with third-line LBCL.
-
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
Gilead was also bolstered by sales of its cell therapy products, which jumped by 36% to $191m in the first quarter, with Yescarta bringing in $160m and Tecartus bringing in $31m.
-
Yescarta gains first FDA approval for indolent follicular lymphoma
marginal zone lymphoma patients were enrolled and treated with Yescarta following two or more prior lines of therapy. ... Kite also recently revealed some positive data for Yescarta in the first-line setting for patients with high-risk large B-cell
More from news
Approximately 15 fully matching, plus 58 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
By Clive Glover. Since the approval of the first five gene or gene-modified cell therapies in the US – Luxturna, Yescarta, Tecartus, Kymriah and Zolgensma – this new technology has been evolving
-
Cortellis Drugs to Watch in 2020 report
as Kymriah and Yescarta.
-
25 Women Leaders in UK Healthcare (part 2)
It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
years. Kymriah’s US list price is $475, 000 while Gilead’s rival drug, Yescarta, is priced at $373, 000 (with European prices substantially lower than this).
-
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta providing an encouraging sign.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
Training the next generation of biotech leaders
In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- EU outlines measures to mitigate antibiotic shortage across Europe
- Europe’s cancer community publishes new report on transforming patient care
- Meeting healthcare’s rising challenges
- Diversifying Healthcare AI with Federated Learning
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval
- UK to introduce new regulatory framework for point of care manufacturing
- Navigating the patient experience to improve retention of clinical trial participants
- Europe’s cancer community publishes new report on transforming patient care
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- EU to revise pharmaceuticals law amid antibiotic shortages
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Why everyone in pharma is bending over backwards to be agile
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
